Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
Rhea-AI Summary
Outlook Therapeutics (Nasdaq: OTLK) reported fiscal 2025 results for the year ended September 30, 2025. The company recorded a net loss of $62.4 million ($1.79 per share) and $1.4 million of revenue from initial European sales of LYTENAVA in June 2025. Gross profit was reduced by increased reserves for short-dated inventory from UK shipments. Operating expenses fell year-over-year driven by lower R&D after completion of NORSE Eight, offset by higher SG&A from the European launch. Cash and equivalents were $8.1 million at September 30, 2025, plus $14.9 million net ATM proceeds received after the period. The FDA PDUFA goal date for ONS-5010 is December 31, 2025.
Positive
- Revenue $1.4M from initial LYTENAVA European sales
- Net loss narrowed from $75.4M to $62.4M year-over-year
- $14.9M net ATM proceeds received after Sept 30, 2025
- LYTENAVA accepted into UK tender framework in December 2025
Negative
- Remaining $62.4M net loss for fiscal 2025
- Gross profit reduced by reserves for short-dated inventory
- Cash and cash equivalents of only $8.1M at Sept 30, 2025
- Increased SG&A expenses from Europe commercial launch
News Market Reaction
On the day this news was published, OTLK declined 2.90%, reflecting a moderate negative market reaction. Argus tracked a trough of -9.8% from its starting point during tracking. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $88M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
OTLK was down 8.81% with elevated volume, while several biotech peers like PSTV (-7.23%) and VRCA (-6.67%) also traded lower and RADX gained 7.23%, suggesting a mixed, stock-specific backdrop rather than a clear sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 24 | Conference participation | Neutral | -4.3% | CEO fireside chat announcement at a healthcare conference. |
| Nov 13 | FDA review update | Positive | +14.8% | FDA accepted ONS-5010 BLA resubmission and set PDUFA date. |
| Nov 03 | BLA resubmission | Positive | +3.2% | Company resubmitted ONS-5010 BLA after Type A meeting. |
| Sep 29 | FDA meeting update | Positive | +9.3% | Completed Type A meeting and planned BLA resubmission. |
| Sep 03 | Conference presentation | Positive | +2.3% | Presentation at EURETINA Innovation Spotlight on retinal treatment. |
Shares have generally reacted positively to regulatory and clinical milestones, with one divergence on a conference-related update.
Over the last six months, Outlook Therapeutics issued several updates around ONS-5010 and its commercialization path. Regulatory communications with the FDA in September–November 2025 and BLA resubmission/acceptance have drawn mostly positive price reactions. Earlier, the company highlighted LYTENAVA’s European commercialization and conference visibility. Today’s fiscal 2025 results fit into this arc of transitioning from a development-stage story toward early commercial execution in Europe while awaiting the U.S. decision.
Market Pulse Summary
This announcement highlights fiscal 2025 results as Outlook Therapeutics begins generating LYTENAVA™ revenue in Europe, reporting $1.4 million in sales and a net loss of $62.4 million. Expenses declined by $4.6 million versus 2024, and cash stood at $8.1 million excluding $14.9 million of later ATM proceeds. With a PDUFA date on December 31, 2025, investors may track U.S. regulatory outcomes and European uptake as key forward metrics.
Key Terms
bevacizumab medical
non-interventional study medical
real-world data medical
at-the-market offering program financial
PDUFA regulatory
AI-generated analysis. Not financial advice.
ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025.
Financial Highlights for the Fiscal Year Ended September 30, 2025
For the fiscal year ended September 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of
Revenue in fiscal 2025 consisted of the initial sales in June 2025 into the sales channels in Germany and the UK for LYTENAVA™ (bevacizumab gamma) where title to the product has transferred to the distributor. Overall, there has been a sustained increase in both the number of accounts ordering LYTENAVA™ and the breadth of prescribing clinicians across both markets during the early stages of fiscal year 2026. In addition to optimal market access and pricing at the national and sub-national level in both the UK and Germany, recent developments that should contribute to continued improvements in unit sales include LYTENAVA™ acceptance into the tender framework in the UK in December 2025 and the initiation of a multi-center non-interventional study in Germany to gather real-world data. Gross profit for fiscal 2025 was impacted negatively due to increased reserves for short-dated inventory included in the original shipments to the UK in June 2025.
Overall expenses in fiscal 2025 were
As of September 30, 2025, Outlook Therapeutics had cash and cash equivalents of
“Over the course of fiscal year 2025, our team has worked diligently to position Outlook Therapeutics for success. We are preparing now for potential approval and progressing commercial launch activities in the U.S., as we await a decision from the FDA in just a few short weeks,” commented Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “In Europe, our initial shipments of inventory are being used to prime and prepare to grow the market. Commercial activities remain ongoing as we push ahead with our efforts to expand into the next wave of country launches, including Austria and the Netherlands. Outside the U.S., we continue to identify potential partners for additional expansion. As we close out the remainder of 2025, our commitment remains focused on providing patients and physicians with access to an approved ophthalmic formulation of bevacizumab.”
Upcoming Near Term Milestone
- U.S. Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is December 31, 2025.
About ONS-5010 / LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)
ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. In certain European Union Member States, ONS-5010/LYTENAVA™ must receive pricing and reimbursement approval before it can be sold.
Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™ would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Forward-Looking Statements
This press release contains statements that are, or may be deemed to be “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “believe,” “can,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, expectations concerning future levels of sales for LYTENAVA™, plans for commercial launch of LYTENAVA™ in additional markets and the timing thereof, expectations concerning decisions of regulatory bodies and the timing thereof, including market exclusivity, the potential to receive approval from the FDA and the timing thereof, the potential of ONS-5010/LYTENAVA™ as a treatment for wet AMD, the market opportunity for LYTENAVA™ in Europe and the United States, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, including the risk that the data from the NORSE EIGHT trial does not support the approval by the FDA of the ONS-5010 BLA, the content and timing of decisions by regulatory bodies, the acceptance of Outlook Therapeutics’ products by healthcare professionals and patients as safe, effective, and cost-effective, the impact of governmental and semi-governmental laws, regulations and guidelines, reliance on third-party service providers, suppliers, and manufacturers, the sufficiency of Outlook Therapeutics’ resources, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the SEC on December 27, 2024, as supplemented by the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025 and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs and trade tensions, fluctuations in interest rates and inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
| Outlook Therapeutics, Inc. | ||||||||||
| Consolidated Statements of Operations | ||||||||||
| (Amounts in thousands, except per share data) | ||||||||||
| Year ended September 30, | ||||||||||
| 2025 | 2024 | |||||||||
| Revenues, net | $ | 1,413 | $ | – | ||||||
| Cost of revenues | 1,356 | – | ||||||||
| Gross profit | 57 | – | ||||||||
| Operating expenses: | ||||||||||
| Research and development | 27,181 | 41,763 | ||||||||
| Selling, general and administrative | 39,938 | 29,940 | ||||||||
| Loss from operations | (67,062 | ) | (71,703 | ) | ||||||
| Loss on equity method investment | 141 | 101 | ||||||||
| Interest income | (90 | ) | (906 | ) | ||||||
| Interest expense | 283 | 3,157 | ||||||||
| Loss from change in fair value of promissory notes | 6,075 | 2,457 | ||||||||
| Warrant related expenses | – | 37,490 | ||||||||
| Warrant inducement expenses | 33,522 | – | ||||||||
| Gain from change in fair value of warrant liability | (43,016 | ) | (38,638 | ) | ||||||
| Loss before income taxes | (63,977 | ) | (75,364 | ) | ||||||
| Income tax (benefit) expense | (1,552 | ) | 3 | |||||||
| Net loss | $ | (62,425 | ) | $ | (75,367 | ) | ||||
| Per share information: | ||||||||||
| Net loss per share of common stock, basic and diluted | $ | (1.79 | ) | $ | (4.06 | ) | ||||
| Weighted average shares outstanding, basic and diluted | 34,796 | 18,549 | ||||||||
| Condensed Consolidated Balance Sheet Data | ||||||||||||
| (Amounts in thousands) | ||||||||||||
| September 30, | ||||||||||||
| 2025 | 2024 | |||||||||||
| Cash and cash equivalents | $ | 8,083 | $ | 14,928 | ||||||||
| Total assets | $ | 18,584 | $ | 28,823 | ||||||||
| Current liabilities | $ | 45,815 | $ | 42,554 | ||||||||
| Total stockholders' deficit | $ | (32,188 | ) | $ | (73,077 | ) | ||||||
FAQ
What is Outlook Therapeutics' FDA PDUFA date for ONS-5010 (OTLK)?
How much revenue did OTLK report for fiscal 2025 from LYTENAVA sales?
What was Outlook Therapeutics' net loss and EPS for fiscal 2025 (OTLK)?
How much cash did Outlook Therapeutics have at Sept 30, 2025 and were there later proceeds?
What commercial milestones did OTLK report in Europe for LYTENAVA in 2025?
Did Outlook Therapeutics reduce R&D spending in fiscal 2025 (OTLK)?
